Aytu BioPharma, Inc. (AYTU)
Oxford Ledge is still expanding full research coverage of AYTU. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Aytu BioPharma commercializes prescription pharmaceuticals, with upcoming focus on EXXUA for depression treatment.
SEC filings
- 8-K Termination of material agreement 2026-06-25
- 10-Q Quarterly financial report (unaudited) 2026-05-13
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-13
- 8-K Entry into material agreement; Results of operations / financial condition; 3.02; 3.03; Financial statements and exhibits 2026-04-02
- 10-Q Quarterly financial report (unaudited) 2026-02-03
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for AYTU. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open AYTU in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.